Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Kre-Celazine
- Development stage
- Preclinical
- Lead developer
- All American Pharmaceutical
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Kre-Celazine is a proprietary nutraceutical compound developed by Dr. Jeff Golini at All American Pharmaceutical. It is a combination of alkali-buffered creatine monohydrate (Kre-Alkalyn) and a mixture of cetylated fatty acids. Originally designed for sports nutrition and athletic performance, it has demonstrated significant anti-inflammatory properties. The buffered creatine component aims to provide the ergogenic benefits of creatine without the typical breakdown into creatinine, while the cetylated fatty acids act as surfactants and anti-inflammatory agents to reduce joint and muscle pain. Notably, it received FDA Orphan Drug Status in 2013 for the treatment of Juvenile Rheumatoid Arthritis (JRA) and Juvenile Idiopathic Arthritis (JIA) after clinical studies showed efficacy in children unresponsive to standard therapies.
- Brand names
- Kre-Celazine
- Other names
- Kre-Celazine®
Beyond the preview
Go deeper on Kre-Celazine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Kre-Celazine.